The FDA extended the Emergency Use Authorization (EUA) for Eli Lilly And Co's (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY) rheumatoid arthritis drug Olumiant (baricitinib)...
Incyte Corporation (INCY) recently notified that its intravenous PD-1 inhibitor, retifanlimab, cannot be approved by the FDA for the treatment of specific cancer patients....
Stocks finally took a break after five days of gains on Tuesday as investors waited on a trio of big tech heavyweights to report after the bell. Meanwhile, the Fed’s...
Investors finally had some bargains to consider on Tuesday, which allowed the market to recover nearly all of yesterday’s sharp selloff. Meanwhile, earnings season reached...
Dates and content of the Prescription Drug User Fee Act are essential for portfolio managers of health-care stocks. A single positive or negative announcement from the U.S. Food...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Sell | Strong Sell | Strong Sell | Sell |
| Technical Indicators | Neutral | Strong Sell | Sell | Strong Sell | Strong Sell |
| Summary | Neutral | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,715.60 | 2,733.20 | 2,710.90 | -6.3 | -0.23% | 1.59M | NASDAQ | |||
| 358.32 | 365.52 | 356.74 | -14.96 | -4.01% | 33.41M | NASDAQ | |||
| 228.40 | 228.53 | 225.91 | +2.57 | +1.14% | 897.72K | NYSE | |||
| 71.60 | 71.78 | 70.51 | +1.31 | +1.86% | 3.38M | NYSE | |||
| 53.70 | 54.10 | 53.32 | +0.63 | +1.19% | 16.89M | NASDAQ | |||
| 197.54 | 201.14 | 194.91 | +1.53 | +0.78% | 23.36M | NYSE | |||
| 196.62 | 198.53 | 193.28 | +1.59 | +0.82% | 19.08M | NASDAQ | |||
| 212.56 | 214.51 | 209.69 | +1.12 | +0.53% | 3.42M | NYSE | |||
| 42.79 | 43.30 | 42.62 | -0.27 | -0.63% | 29.02M | NYSE | |||
| 153.00 | 153.87 | 151.91 | +1.30 | +0.86% | 9.06M | NYSE | |||
| 11.49 | 11.64 | 11.47 | -0.02 | -0.17% | 7.35M | NASDAQ | |||
| 283.17 | 289.00 | 281.60 | -18.81 | -6.23% | 18.24M | NASDAQ | |||
| 72.04 | 76.50 | 70.35 | -4.61 | -6.01% | 27.09M | NYSE | |||
| 141.93 | 142.96 | 141.60 | +0.16 | +0.11% | 2.67M | NYSE | |||
| 2.53 | 2.56 | 2.52 | -0.050 | -1.94% | 6.79M | NYSE |
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
